The treatment of bisphosphonateassociated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors

Journal of the American Dental Association

Volumn 138, Issue 7, 2007, Pages 971-977

  Adornato, Michael C ^a,b,c   Morcos, Iyad ^b   Rozanski, James ^b  

^a Oral and Maxillofacial Surgery   (United States)

^b Faxton St Luke's Healthcare Dental Services   (United States)

^c Faxton St Luke's Healthcare Dental Services ^*  (United States)

Author keywords

Bisphosphonate associated osteonecrosis; Bisphosphonates; Bone healing; Marginal bone resection; Mucosal healing; Platelet derived growth factors; Platelet rich plasma

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; PLATELET DERIVED GROWTH FACTOR;

ADULT; AGED; ARTICLE; ARTIFICIAL MEMBRANE; BONE NECROSIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; JAW DISEASE; MALE; METHODOLOGY; MIDDLE AGED; ORAL SURGERY; THROMBOCYTE RICH PLASMA;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; PLATELET-DERIVED GROWTH FACTOR; PLATELET-RICH PLASMA;

EID: 34547478153     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2007.0294     Document Type: Article

References (17)

1. Homes SM. Increasing reports of osteonecrosis associated with use of Bisphosphonates. The Monitor 2005;16(3):6.
2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg2003;61(9):1115- 7.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62(5):527-34.
4. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 2005;39(4):668-77. Epub 2005 Mar 8.
5. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90(3):1897-9.
6. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34(2):120-3.
7. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper (published correction appears in JADA 2006;137[1]:26). JADA 2005;136(12):1658-68.
8. Carter GD, Goss AN. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 2003;48(4):268.
9. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg 2004;62(3):391-2.
10. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21(22):4253-4.
11. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. JADA 2005;136(12):1675-81.
12. Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85(6):638-46.
13. Dugrillon A, Eichler H, Kern S, Kluter H. Autologous concentrated platelet-rich plasma (cPRP) for local application in bone regeneration. Int J Oral Maxillofac Surg 2002;31(6):615-9.
14. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004;62(4):489-96.
15. Jones LC, Mont MA, Le TB, et al. Procoagulants and osteonecrosis. J Rheumatol 2003;30(4):783-91.
16. Kapitola J, Zak J, Lacinova Z, Justova V. Effect of growth hormone and Pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res 2000;49(supplement 1):S101-6.
17. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62(22):6538-44.